Title :Dr. Yang Yushe, Shanghai Institute of Materia Medica, CAS: Fresh Perspectives on the Discovery of Clinical Drug Candidates   

Speaker :Dr. Yang Yushe (Principal Investigator)   

Host :Prof. Zeng Wei   

Time :11:05 – 11:50 a.m., 27 December 2025   

Venue :Meeting Room, 4th Floor of the Shaw Engineering Building, School of Chemistry & Chemical Engineering, Wushan Campus   

Organizers :School of Chemistry & Chemical Engineering, Guangdong Provincial Key Laboratory of Functional Molecular Engineering   

[Brief profile]

Dr. Yang Yushe is a Level-2 Principal Investigator, Ph.D. supervisor, and team leader at both the Shanghai Institute of Materia Medica (CAS) and the CAS-Zhongshan Innovation Institute for Drug Discovery. His research focuses on the discovery and development of first-in-class anti-infective, anti-tumor, and central-nervous-system drugs.   

In 2009 he successfully developed China’s first self-owned fluoroquinolone antibacterial, antofloxacin hydrochloride, a milestone widely covered by CCTV and other national media. Since then he has independently advanced six additional clinical candidates, including the oxazolidinone anti-MRSA agent YG-056SP, the pyrimidinetrione anti-drug-resistant gonococcus agent YZS-103, and the anti-multidrug-resistant Gram-negative pathogen agent YJF-36. Most of these candidates have been out-licensed and moved into clinical trials.   

He has published more than 80 research papers in journals such as J. Med. Chem. and filed 60 domestic and international patent applications. Among his honors are the 2017 National Technological Invention Award (1st awardee) and the 2015 Shanghai Technological Invention Award (1st awardee). In 2010 he was named “Shanghai Model Worker.”

Announced by School of Chemistry and Chemical Engineering.